Literature DB >> 16162791

Effect of beta-blockers on cardiac function and calcium handling protein in postinfarction heart failure rats.

Yi-Lan Sun1, Shen-Jiang Hu, Li-Hong Wang, Ying Hu, Jian-Ying Zhou.   

Abstract

OBJECTIVES: The normal expression of Ca2+-handling protein is critical for efficient myocardial function. The present study was designed to test the hypothesis that beta-blocker treatment may attenuate left ventricular (LV) remodeling and cardiac contractile dysfunction in the failing heart, which may be associated with alterations of Ca2+-handling protein
METHODS: We investigated the change of LV remodeling and function in a rat model of heart failure due to myocardial infarction (MI) with or without carvedilol (30 mg/kg/d) or metoprolol (60 mg/kg/d) treatment for 6 weeks (n = 9 in the MI plus carvedilol group, and n = 8 in every other group). The expression of messenger RNA and proteins of sarcoplasmic reticulum Ca2+-adenosine triphosphatase (SERCA) and phospholamban in cardiomyocytes of all rats were also measured
RESULTS: There was significant LV remodeling and cardiac contractile dysfunction in MI rats. The messenger RNA and protein expression of SERCA were down-regulated (p < 0.01), but the expression of phospholamban messenger RNA and protein were up-regulated (p < 0.01) in MI rats compared to sham-operated rats. After the treatment with beta-blockers, LV remodeling and function were clearly improved. Carvedilol was better in attenuating the weight of the LV and the relative weight of the right ventricle than metoprolol (p < 0.05). beta-Blockers restored the low expression of SERCA (p < 0.05) but showed no effect on phospholamban expression (p > 0.05). Moreover, carvedilol induced a more significant improvement of SERCA expression than metoprolol (p < 0.05)
CONCLUSIONS: Beta-blockers are effective in preventing LV remodeling and cardiac contractile dysfunction in the failing heart. The molecular mechanism may be related to normalization of SERCA expression.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16162791     DOI: 10.1378/chest.128.3.1812

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  10 in total

1.  Remodelling of action potential and intracellular calcium cycling dynamics during subacute myocardial infarction promotes ventricular arrhythmias in Langendorff-perfused rabbit hearts.

Authors:  Chung-Chuan Chou; Shengmei Zhou; Hideki Hayashi; Motoki Nihei; Yen-Bin Liu; Ming-Shien Wen; San-Jou Yeh; Michael C Fishbein; James N Weiss; Shien-Fong Lin; Delon Wu; Peng-Sheng Chen
Journal:  J Physiol       Date:  2007-02-01       Impact factor: 5.182

2.  β-Adrenergic receptor antagonists ameliorate myocyte T-tubule remodeling following myocardial infarction.

Authors:  Biyi Chen; Yue Li; Shuxia Jiang; Yu-Ping Xie; Ang Guo; William Kutschke; Kathy Zimmerman; Robert M Weiss; Francis J Miller; Mark E Anderson; Long-Sheng Song
Journal:  FASEB J       Date:  2012-02-28       Impact factor: 5.191

3.  Acipimox-enhanced ¹⁸F-fluorodeoxyglucose positron emission tomography for characterizing and predicting early remodeling in the rat infarct model.

Authors:  Mélanie Bousquenaud; Fatiha Maskali; Sylvain Poussier; Pierre-Yves Marie; Henri Boutley; Gilles Karcher; Daniel R Wagner; Yvan Devaux
Journal:  Int J Cardiovasc Imaging       Date:  2011-11-25       Impact factor: 2.357

4.  Mechanisms of the beneficial effects of beta-adrenoceptor antagonists in congestive heart failure.

Authors:  Navneet S Rehsia; Naranjan S Dhalla
Journal:  Exp Clin Cardiol       Date:  2010

5.  Effects of treatment with a 5-HT4 receptor antagonist in heart failure.

Authors:  J A K Birkeland; I Sjaastad; T Brattelid; E Qvigstad; E R Moberg; K A Krobert; R Bjørnerheim; T Skomedal; O M Sejersted; J-B Osnes; F O Levy
Journal:  Br J Pharmacol       Date:  2006-12-11       Impact factor: 8.739

Review 6.  A pathway and network review on beta-adrenoceptor signaling and beta blockers in cardiac remodeling.

Authors:  Jihong Yang; Yufeng Liu; Xiaohui Fan; Zheng Li; Yiyu Cheng
Journal:  Heart Fail Rev       Date:  2014-11       Impact factor: 4.214

7.  Polygenic Score for β-Blocker Survival Benefit in European Ancestry Patients With Reduced Ejection Fraction Heart Failure.

Authors:  David E Lanfear; Jasmine A Luzum; Ruicong She; Hongsheng Gui; Mark P Donahue; Christopher M O'Connor; Kirkwood F Adams; Sandra Sanders-van Wijk; Nicole Zeld; Micha T Maeder; Hani N Sabbah; William E Kraus; Hans-Peter Brunner-LaRocca; Jia Li; L Keoki Williams
Journal:  Circ Heart Fail       Date:  2020-10-04       Impact factor: 8.790

8.  Carvedilol Selectively Stimulates βArrestin2-Dependent SERCA2a Activity in Cardiomyocytes to Augment Contractility.

Authors:  Jennifer Maning; Victoria L Desimine; Celina M Pollard; Jennifer Ghandour; Anastasios Lymperopoulos
Journal:  Int J Mol Sci       Date:  2022-09-26       Impact factor: 6.208

9.  Carvedilol prevents ovariectomy-induced myocardial contractile dysfunction in female rat.

Authors:  Rogerio Faustino Ribeiro; Felipe F Potratz; Brunella M M Pavan; Ludimila Forechi; Filipe Lugon Moulin Lima; Jonaina Fiorim; Aurelia Araujo Fernandes; Dalton Valentim Vassallo; Ivanita Stefanon
Journal:  PLoS One       Date:  2013-01-07       Impact factor: 3.240

10.  Reversal of subcellular remodelling by losartan in heart failure due to myocardial infarction.

Authors:  Andrea Babick; Donald Chapman; Shelley Zieroth; Vijayan Elimban; Naranjan S Dhalla
Journal:  J Cell Mol Med       Date:  2012-12       Impact factor: 5.310

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.